Breast cancer stage I – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Breast cancer stage I – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pre-Operative Treatment for Breast Cancer Using Nivolumab, Ipilimumab, and Relatlimab for Patients with Breast Cancer https://clinicaltrials.eu/trial/study-on-pre-operative-treatment-for-breast-cancer-using-nivolumab-ipilimumab-and-relatlimab-for-patients-with-breast-cancer/ Wed, 29 Apr 2026 15:02:16 +0000 https://clinicaltrials.eu/trial/study-on-pre-operative-treatment-for-breast-cancer-using-nivolumab-ipilimumab-and-relatlimab-for-patients-with-breast-cancer/ This clinical trial is focused on studying treatments for breast cancer. The trial involves the use of several medications, including nivolumab, ipilimumab, and relatlimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The purpose of the study is to determine if these medications, either alone or in combination, can help achieve a complete response in the cancer before surgery. A complete response means that no cancer cells are found in the breast or nearby lymph nodes when examined under a microscope.

Participants in the study will receive treatment with these medications for a short period before their scheduled surgery. The study will monitor how well the cancer responds to the treatment and will also keep track of any side effects that may occur. The trial aims to understand the effectiveness of these medications in shrinking the cancer and improving outcomes for patients with breast cancer.

Throughout the study, various assessments will be conducted, including imaging tests like MRI to evaluate the response of the cancer to the treatment. The study will also look at the overall survival and event-free survival of participants, which refers to the length of time patients live without the cancer returning or worsening. By exploring these treatments, the trial hopes to find new ways to improve the management of breast cancer and enhance the quality of life for those affected by this disease.

]]> Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ Wed, 29 Apr 2026 15:00:29 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ This study focuses on patients with HER2-negative breast cancer who still have residual disease after receiving standard neoadjuvant chemotherapy and are at high risk of cancer returning. The main treatment being investigated is sacituzumab govitecan, which is a specialized medication that combines an antibody with an anti-cancer drug, designed to target specific cancer cells.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

]]> Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-alone-and-with-pembrolizumab-for-patients-with-low-risk-triple-negative-early-breast-cancer/ Wed, 29 Apr 2026 14:30:36 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-alone-and-with-pembrolizumab-for-patients-with-low-risk-triple-negative-early-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple-negative early breast cancer, which is considered to have a low risk of coming back after treatment. The study is comparing two treatment options: one using a medication called sacituzumab govitecan and the other combining sacituzumab govitecan with another medication called pembrolizumab. Sacituzumab govitecan is a type of drug that targets cancer cells, while pembrolizumab helps the immune system fight cancer.

The purpose of the study is to see if the combination of sacituzumab govitecan and pembrolizumab is more effective than sacituzumab govitecan alone. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 18 months, during which time participants will receive regular treatments and follow-up care to monitor their health and the effectiveness of the treatment.

Throughout the study, doctors will check for the absence of cancer in the breast and lymph nodes, which is known as a complete response. They will also track the participants’ health over three years to see if the cancer stays away. The study aims to improve treatment options for people with this type of breast cancer and to increase the chances of long-term health and recovery.

]]> Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-paclitaxel-for-early-triple-negative-breast-cancer-in-patients-with-high-tumor-infiltrating-lymphocytes/ Wed, 29 Apr 2026 14:28:55 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-paclitaxel-for-early-triple-negative-breast-cancer-in-patients-with-high-tumor-infiltrating-lymphocytes/ This clinical trial is focused on studying Triple Negative Breast Cancer, a type of breast cancer that does not have hormone receptors or the HER2 protein receptor. The study will explore the effects of a treatment involving a combination of two medications: pembrolizumab and paclitaxel. Pembrolizumab is a type of immunotherapy that helps the immune system fight cancer, while paclitaxel is a chemotherapy drug that works by stopping cancer cells from growing. The purpose of the study is to understand how effective this combination treatment is in preventing the return of cancer in patients who have had early-stage triple-negative breast cancer removed surgically.

Participants in the study will be divided into two groups. One group will receive the combination of pembrolizumab and paclitaxel, while the other group will be under standard surveillance, meaning they will not receive additional treatment after surgery. The study will monitor participants over a period of time to see how well the treatment works in preventing cancer from coming back. The study will also look at the safety and tolerability of the treatment, as well as its impact on the quality of life of the participants.

The trial will assess the outcomes over several years, focusing on whether the cancer returns, if new cancers develop, and overall survival rates. The study aims to provide valuable information on the effectiveness of using pembrolizumab and paclitaxel together in treating early-stage triple-negative breast cancer, potentially offering new insights into managing this challenging type of cancer.

]]>